Cardiff Oncology (CRDF) SEC Filings & 10K Form $3.44 -0.10 (-2.82%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.53 +0.09 (+2.73%) As of 03/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recent Cardiff Oncology SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView02/27/20253:11 PMCardiff Oncology, Inc. (Filer)Cardiff Oncology (Filer)Form S-3Registration statement under Securities Act of 1933 02/27/20253:15 PMCardiff Oncology, Inc. (Filer)Cardiff Oncology (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/27/20253:00 PMCardiff Oncology, Inc. (Filer)Cardiff Oncology (Filer)Form 10-KAnnual report pursuant to Section 13 or 15(d) 02/12/20251:48 PMCardiff Oncology, Inc. (Subject)Cardiff Oncology (Subject)PFIZER INC (Filed by)Form SCHEDULE 13G/A12/18/20243:37 PMCardiff Oncology, Inc. (Issuer)Cardiff Oncology (Issuer)Levine James E. (Reporting)Form 4Statement of changes in beneficial ownership of securities 12/17/20243:06 PMCardiff Oncology, Inc. (Subject)Cardiff Oncology (Subject)COMMODORE CAPITAL LP (Filed by)Form SCHEDULE 13G12/16/20244:00 PMCardiff Oncology, Inc. (Issuer)Cardiff Oncology (Issuer)TANNENBAUM RENEE P (Reporting)Form 4Statement of changes in beneficial ownership of securities 12/11/20245:15 AMCardiff Oncology, Inc. (Filer)Cardiff Oncology (Filer)Form 424B512/10/20245:02 AMCardiff Oncology, Inc. (Filer)Cardiff Oncology (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 10/24/20241:02 PMBlackRock, Inc. (Filed by)Cardiff Oncology, Inc. (Subject)Cardiff Oncology (Subject)Form SC 13G06/17/20245:10 AMCardiff Oncology, Inc. (Filer)Cardiff Oncology (Filer)Form DEFA14A06/03/20243:06 PMCardiff Oncology, Inc. (Filer)Cardiff Oncology (Filer)Form DEFA14A(Data available from 1/1/2016 forward) Remove Ads Related Companies and Tools Related Companies Vir Biotechnology SEC Filings Intellia Therapeutics SEC Filings Collegium Pharmaceutical SEC Filings Arcus Biosciences SEC Filings Rocket Pharmaceuticals SEC Filings Xencor SEC Filings Zymeworks SEC Filings Xeris Biopharma SEC Filings Phibro Animal Health SEC Filings Gyre Therapeutics SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:CRDF) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
